Search hospitals > Oregon > Ontario

Saint Alphonsus Medical Center-Ontario

Claim this profile
Ontario, Oregon 97914
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
185 reported clinical trials
2 medical researchers
Photo of Saint Alphonsus Medical Center-Ontario in OntarioPhoto of Saint Alphonsus Medical Center-Ontario in OntarioPhoto of Saint Alphonsus Medical Center-Ontario in Ontario

Summary

Saint Alphonsus Medical Center-Ontario is a medical facility located in Ontario, Oregon. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Saint Alphonsus Medical Center-Ontario is involved with conducting 185 clinical trials across 364 conditions. There are 2 research doctors associated with this hospital, such as John M. Schallenkamp and Benjamin T. Marchello.

Area of expertise

1Cancer
Global Leader
Saint Alphonsus Medical Center-Ontario has run 89 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
Stage II
2Breast Cancer
Global Leader
Saint Alphonsus Medical Center-Ontario has run 32 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
Stage IV
ER positive

Top PIs

Clinical Trials running at Saint Alphonsus Medical Center-Ontario

Breast Cancer
Cancer
Bladder Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Bladder Carcinoma
Colon Cancer
Squamous Cell Carcinoma
Oropharyngeal Carcinoma
Ovarian Cancer
Image of trial facility.

Pembrolizumab

for Triple-Negative Breast Cancer

The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Image of trial facility.

Shorter Chemo-Immunotherapy Without Anthracyclines

for Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Image of trial facility.

Durvalumab + Chemotherapy

for Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint Ultrahigh (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint Ultrahigh Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Saint Alphonsus Medical Center-Ontario?
Saint Alphonsus Medical Center-Ontario is a medical facility located in Ontario, Oregon. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Saint Alphonsus Medical Center-Ontario is involved with conducting 185 clinical trials across 364 conditions. There are 2 research doctors associated with this hospital, such as John M. Schallenkamp and Benjamin T. Marchello.